This Article Full Text (OnlineFirst PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Tenback, D. Articles by van Os, J PubMed PubMed Citation Articles by Tenback, D. Articles by van Os, J Social Bookmarking                         What's this?

Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia

¹ Psychiatric Center Symfora Group, Amersfoort, The Netherlands; Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
² Psychiatric Center Symfora Group, Amersfoort, The Netherlands; Department of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands
³ Department of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands; Department of Psychotic Disorders, Mental Health Centre Drenthe, Assen, The Netherlands
⁴ Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, Maastricht, The Netherlands; Division of Psychological Medicine, Institute of Psychiatry, London, UK

^* To whom correspondence should be addressed.

	Abstract

Abstract

Although it has been suggested that second-generation antipsychotics (SGA) may reduce the rate of prevalent tardive dyskinesia (TD), little is known about the incidence and outcome of TD in those exposed exclusively to SGA. The incidence and subsequent persistence of TD and extrapyramidal symptoms (EPS) was calculated in a cohort of patients with schizophrenia treated predominantly with SGA. This cohort of more than 10,000 patients with schizophrenia was seen six times over a period of two years. Dichotomous measures of EPS and TD were used to calculate the yearly incidence rates of TD and EPS as well as their subsequent cumulative persistence rate in a subset of 9104 and 6285 patients at risk for TD and EPS, respectively. Of 9104 individuals who did not present with TD at baseline, 138 developed TD, yielding a TD incidence rate of 0.74% (95% CI: 0.62, 0.87) and a subsequent cumulative persistence rate of 80%. Of 6285 individuals without EPS at baseline, 464 developed EPS yielding an incidence rate of 3.7% (95% CI: 3.4, 4.0) and a subsequent cumulative persistence rate of 82%. Incidence rates of TD and EPS may be low in the SGA era. However, once emerged, these disorders prove persistent, suggesting strong moderators effects of underlying predisposing factors.

Key Words: epidemiology, extrapyramidal, longitudinal, schizophrenia, tardive dyskinesia

First published on June 1, 2009
Journal of Psychopharmacology 2009, doi:10.1177/0269881109106306


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?